|
Future of bioprocessing will depend on combining scientific innovation with manufacturing excellence: Expert
|
|
Yash Ved, Mumbai
October 13 , 2026
|
|
|
Bioprocessing is a vital part of the pharmaceutical industry, supporting the development and manufacture of vaccines, monoclonal antibodies, recombinant proteins, enzymes, and advanced therapies. As healthcare needs continue to evolve, the industry must strengthen existing capabilities while pursuing long-term priorities, including affordable medicines, dependable supply, faster development, and sustainable production, according to Nihal Bharadwaj, Bioprocess Leader, downstream manufacturing Specialist, Dr Reddy's Laboratories.
Bharadwaj stated that the future of pharmaceutical bioprocessing will depend on combining scientific innovation with manufacturing excellence. Strategic investment in people, infrastructure, sustainable technologies, and collaborative biohubs can strengthen product quality and supply reliability while supporting the development of effective medicines for patients worldwide, across diverse healthcare systems and populations.
Bharadwaj added “Modern bioprocessing integrates upstream operations, such as cell culture and fermentation, with downstream purification, formulation, and quality control. Products manufactured through these processes include biosimilars, therapeutic monoclonal antibodies, recombinant insulin, viral-vector therapies, cell-based treatments, mRNA vaccines, and diagnostic proteins. Their consistent production requires robust process design, qualified equipment, contamination control, analytical characterization, and compliance with Good Manufacturing Practices (GMP). Process intensification, single-use technologies, continuous manufacturing, and data-driven monitoring can improve productivity and consistency when appropriately assessed and validated.”
Achieving future goals will require investment throughout the innovation pathway. Government research grants, biotechnology funding agencies, venture capital, pharmaceutical companies, and academic-industry partnerships all have a role in translating promising discoveries into viable products,” stated Bharadwaj
“Investment must extend beyond laboratory research to include pilot-scale facilities, skilled personnel, quality systems, regulatory expertise, and technology transfer. Supporting scale-up at an early stage can help bridge the gap between laboratory development and reliable commercial manufacturing. Funding strategies should also promote affordability, manufacturing resilience, and sustainable access,” stated Bharadwaj.
Bharadwaj further stated, “Biohubs can accelerate this progress by providing shared infrastructure and expertise. Biofoundries and biomanufacturing hubs offer access to specialized equipment, pilot-scale facilities, technical support, and training for start-ups, universities, small businesses, and established manufacturers. In India, the BioE3 policy supports high-performance biomanufacturing and the development of Biofoundries and Biomanufacturing Hubs. These platforms can encourage collaboration, process optimization, scale-up, and the transition from research to commercial production. Their success will depend on accessible facilities, effective governance, industry participation, and clear pathways toward regulatory readiness.”
Bioprocessing also helps address significant unmet medical needs. Biopharmaceutical products can contribute to the prevention and treatment of cancer, autoimmune disorders, infectious diseases, diabetes, and certain rare or genetic conditions.
Advances in precision medicines, including antibody-based treatments, mRNA technologies, and cell and gene therapies, may broaden therapeutic options. However, safety, efficacy, manufacturing costs, and equitable access must remain central considerations, added Bharadwaj.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|